With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
Guidepoint Qsight, a leader in leveraging proprietary data to provide unmatched analytics solutions, today revealed new ...
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...
GLP-1 drugs, such as Wegovy and Ozempic, are gaining popularity in the US and Europe for their appetite-suppressing ...
Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.
The Study is designed mainly to determine whether Lexaria’s proprietary DehydraTECH technology improves the safety and effectiveness of existing GLP-1 drugs. “Achieving the first patient, first dose ...
Hims & Hers stock took a hit today after the FDA ruled no shortage of tirzepatide, impacting their compounded GLP-1 drug offerings. Despite the setback, Hims & Hers' CEO will likely remain defiant ...
Merck is finally making a move in obesity by licensing an oral GLP-1 candidate, though it’s happening years after some of its big pharma peers … ...
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. The Big Pharma already has efinopegdutide, a dual GLP-1 ...
Nestlé’s efforts to attract users of GLP-1 drugs in the US now include the launch of protein shots. The company is rolling out Boost Pre-meal, a liquid shot the Swiss giant said will “support people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback